Shane Schaffer@shaneschaffer
Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, a Phase 3 clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas. The company is a leader in the development of next-generation pharmaceutical products, with a focus on Attention Deficit/Hyperactivity Disorder (ADHD), anxiety disorders, and insomnia.
With 25 years in the pharmaceutical industry, Dr. Schaffer is a drug development and commercialization expert. His leadership is marked by an entrepreneurial spirit and a strategic approach to product launches, brand planning, joint venture brand management, life cycle management, and market development, making him a notable figure in biopharmaceutical and marketing.
He completed his doctoral degree in Pharmacy at the University of Kansas in 1999, followed by a postdoctoral fellowship at Rutgers University's College of Pharmacy. During his fellowship, he worked with Pfizer Worldwide Marketing and Morris Plains, where he developed key skills in pharmaceutical marketing and strategy.
While at Pfizer Worldwide Marketing in New York, NY, he served as a Marketing Manager, spearheading the development of pre-launch strategies and the Global Communications Intranet, enhancing communication between medical and marketing teams. In Morris Plains, New Jersey, he excelled as a Project Manager and External Research Manager, overseeing advanced sales training and managing Phase IV Medical Research across all marketed brands.
His career progression saw him hold pivotal roles at Pfizer, Novartis, and Sanofi. At Novartis, he managed the Ritalin® LA and Focalin™ segments, driving significant market growth and product awareness. These efforts earned him the Novartis Business Excellence Award, among other accolades.
After Novartis, he continued his success at Sanofi, where he played a crucial role in strategic initiatives during the company's mergers and joint ventures, particularly with products like Avapro and Avalide. He also led promotional strategies for Hyalgan, Eligard, and Arixtra, resulting in high sales performance and several Sanofi Star Awards.
In October 2008, he transitioned to M|C Communications LLC in Boston as a consultant, leading business development for primary pharmaceutical targets. In July 2009, he founded Sabre Scientific Solutions, LLC, offering consultancy services in commercials, clinical operations, product launches, and leadership consulting.
Driven by a passion for improving treatments for ADHD and anxiety disorders, he established Cingulate Therapeutics LLC in January 2013. Under his leadership, the company has partnered with Indegene to market the oral ADHD medication CTx-1301, now in Phase 3 trials, with plans to submit a new drug application to the FDA by mid-2025.
Beyond his professional endeavors, Shane Schaffer is actively involved in philanthropy, particularly with the Folds of Honor Charity, which provides educational scholarships to children of fallen or disabled military personnel. This demonstrates his commitment to his industry and community welfare.